Celldex Therapeutics, Inc. is a biopharmaceutical company focused on mast cell biology, developing therapeutic monoclonal and bispecific antibodies for severe inflammatory, allergic, and autoimmune diseases. Its lead candidate, Barzolvolimab (CDX-0159), a KIT receptor inhibitor, is in Phase 3 trials for Chronic Spontaneous Urticaria and Phase 2 trials for Prurigo Nodularis and Atopic Dermatitis. Its bispecific pipeline includes CDX-622, targeting TSLP and SCF for inflammatory diseases.
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001104659-26-019652 | EDGAR | 78K words |
| 2025-02-27 | 2024-12-31 | 0001410578-25-000216 | EDGAR | — |
| 2024-02-26 | 2023-12-31 | 0001410578-24-000076 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001104659-23-026701 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001104659-22-028070 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001104659-21-043161 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001047469-20-001809 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001047469-19-000992 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001047469-18-001363 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001047469-17-001564 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001104659-25-109137 | EDGAR | 24K words |
| 2025-08-07 | 2025-06-30 | 0001410578-25-001610 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001410578-25-001111 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001410578-24-001766 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001410578-24-001219 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001410578-24-000593 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001410578-23-002169 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001410578-23-001588 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001104659-23-055992 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001104659-22-116466 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001104659-22-087222 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001104659-22-056442 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001104659-26-038882 | EDGAR | 25K words |
| 2026-02-25 | 0001171843-26-001098 | EDGAR | — |
| 2025-11-10 | 0001171843-25-007179 | EDGAR | — |
| 2025-08-19 | 0001104659-25-080248 | EDGAR | — |
| 2025-08-07 | 0001171843-25-005181 | EDGAR | — |
| 2025-06-06 | 0001104659-25-057066 | EDGAR | — |
| 2025-05-08 | 0001171843-25-002980 | EDGAR | — |
| 2025-02-27 | 0001171843-25-001126 | EDGAR | — |
| 2024-11-06 | 0001171843-24-006056 | EDGAR | — |
| 2024-08-08 | 0001171843-24-004603 | EDGAR | — |
334 total filings indexed. 302 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000744218 |
| Ticker | CLDX |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.celldex.com |
| Listed | 1986-05-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report